MED1/BDNF/TrkB pathway is involved in thalamic hemorrhage-induced pain and depression by regulating microglia
Laboratory studyOther animalsHumansWith luteolin (co-ultramicronised PEA plus luteolin, PEALut)
This study tested palmitoylethanolamide together with luteolin (co-ultramicronised PEA plus luteolin, PEALut). Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Laboratory study
- Subjects
- Mice with thalamic haemorrhage induced by collagenase injection; human post-mortem brain specimens after stroke; numbers not stated in the abstract
- Dose used in the study
- Repeated administrations of co-ultramicronised PEALut; dose and route not stated in the abstract
- Duration
- 28-day observation period
- What was measured
- Mechanical hypersensitivity, microglial activation, depressive-like behaviour, synaptic plasticity, monoamine levels and MED1, TrkB and BDNF expression in mice; MED1 in human post-stroke brain tissue.
What the authors reported
This laboratory study found:
- Repeated PEALut significantly reduced mechanical hypersensitivity compared with vehicle, reduced early microglial activation and prevented depressive-like behaviour at 21 days.
- It restored synaptic plasticity, monoamine levels and MED1/TrkB/BDNF expression.
- MED1 was also overexpressed in human brain specimens after stroke.
Limits of this study
A mouse model of post-stroke pain; it cannot show effect in people. Palmitoylethanolamide was combined with luteolin, so PEA alone was not tested. Dose is not in the abstract. Funding and conflicts not stated in the abstract.
Source
PubMed 34995755 · doi:10.1016/j.nbd.2022.105611
Entry checked against the abstract on PubMed on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.